<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Depersonalization/derealization disorder: Epidemiology, clinical features, assessment, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Depersonalization/derealization disorder: Epidemiology, clinical features, assessment, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Depersonalization/derealization disorder: Epidemiology, clinical features, assessment, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daphne Simeon, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Spiegel, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H10290103"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Depersonalization/derealization disorder (DDD) is characterized by the persistence or recurrence of depersonalization and/or derealization that cause clinically significant distress or impairment in the presence of intact reality testing [<a href="#rid1">1</a>].</p><p>DDD has a prevalence of approximately 2 percent and is associated with significant morbidity, but often goes undetected or misdiagnosed, leading to delays in treatment.</p><p>This topic discusses the epidemiology, pathogenesis, clinical manifestations, course, and diagnosis of DDD. Our approach to selecting among treatments for DDD is discussed separately. Individual medications and psychotherapies for DDD are also discussed separately. (See  <a class="medical medical_review" href="/z/d/html/108150.html" rel="external">"Depersonalization/derealization disorder: Treatment overview"</a> and  <a class="medical medical_review" href="/z/d/html/14695.html" rel="external">"Depersonalization/derealization disorder: Psychotherapy"</a>.)</p><p class="headingAnchor" id="H4209037600"><span class="h1">DEFINITIONS</span></p><p class="headingAnchor" id="H1018201362"><span class="h2">Depersonalization</span><span class="headingEndMark"> — </span>Depersonalization is a persistent or recurrent feeling of detachment or estrangement from one’s self. An individual experiencing depersonalization may report feeling like an automaton or as if in a dream or as if watching himself or herself in a movie. Depersonalized individuals may report the sense of being an outside observer of their mental processes or their body. They often report feeling a loss of control over their thoughts, perceptions, and actions.</p><p class="headingAnchor" id="H494158745"><span class="h2">Derealization</span><span class="headingEndMark"> — </span>Derealization is a subjective sense of detachment or unreality regarding the world around them (eg, individuals or objects are experienced as unreal, dreamlike, foggy, lifeless, or visually distorted).</p><p class="headingAnchor" id="H10289528"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H2022939"><span class="h2">Prevalence</span><span class="headingEndMark"> — </span>Transient experiences of depersonalization and derealization are very common in the general population [<a href="#rid2">2</a>]. In a nonurban United States sample, the one-year prevalence of depersonalization symptoms was approximately 20 percent [<a href="#rid3">3</a>]. In a large normative sample of German adolescents, 12 percent reported clinically significant depersonalization [<a href="#rid4">4</a>]. Approximately half of college students in another United States study reported experiencing an episode of depersonalization in the past year. Adolescents and young adults appear to be at the highest risk for reporting such symptoms, possibly because their sense of self is still fluid and developmentally unstable.</p><p>Transient depersonalization symptoms, which may be primary or secondary to another condition, are more common than depersonalization/derealization disorder (DDD). Studies from several countries including the United States, Canada, United Kingdom, Turkey, and Germany have shown a lifetime prevalence for DDD in the range of 0.8 percent to 2.8 percent [<a href="#rid5">5-7</a>], comparable to that of other psychiatric disorders such as schizophrenia, bipolar disorder, and obsessive-compulsive disorder.</p><p class="headingAnchor" id="H2022925"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>DDD has been found to be equally common in males and females in clinical samples [<a href="#rid8">8,9</a>]. In up to half of cases there is no readily identifiable proximal precipitant [<a href="#rid8">8</a>]. Common risk factors for DDD include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute and chronic trauma or severe stress.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Psychiatric conditions, most commonly anxiety or depressive disorders – Chronic depersonalization and derealization symptoms meeting diagnostic criteria for the disorder have also been reported to begin during severe or prolonged episodes of a mood or anxiety disorder, which may destabilize the sense of usual expected self and in itself act as a powerful internal stressor [<a href="#rid8">8</a>]. This pattern occurs in approximately one-third of all patients with DDD. Typically, in this scenario, the depersonalization and derealization symptoms set in at some point of escalation of the original disorder, but persist or worsen on a long-term basis after the precipitating disorder has spontaneously remitted or been treated, taking on an independent course, a “life of its own.”</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alexithymia – Additionally, there is evidence of elevated rates of alexithymia in those suffering from DDD, with nearly half of participants demonstrating high or moderate alexithymia in one study [<a href="#rid10">10</a>]. This difficulty in identifying and processing emotions is likely not simply an outcome of the disorder, but is a risk factor for its genesis, as alexithymic individuals have greater difficulty with the emotional processing of traumatic and stressful events.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fearful attachment style – There is a high prevalence of insecure attachment in DDD, with a preponderance of fearful attachment style [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Substance use disorder.</p><p></p><p>Chronic depersonalization and derealization has been reported in as many as one-third to one-half of individuals experiencing chronic traumatic or highly stressful situations. Examples of these situations include (see <a class="local">'Role of trauma'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>Childhood abuse or neglect</p><p class="bulletIndent1"><span class="glyph">●</span>Unexpected death of a loved one</p><p class="bulletIndent1"><span class="glyph">●</span>Growing up with a seriously mentally ill parent or caregiver</p><p class="bulletIndent1"><span class="glyph">●</span>Sexual orientation/identity conflicts in adolescence and young adulthood</p><p class="bulletIndent1"><span class="glyph">●</span>Serious relationship or work stressors</p><p></p><p class="headingAnchor" id="H2022763"><span class="h2">Comorbid conditions</span><span class="headingEndMark"> — </span>Based on clinical samples, DDD appears to have high rates of comorbidity with other psychiatric disorders. As an example, in a study of 117 United States adults with DDD [<a href="#rid8">8</a>], the lifetime prevalence of comorbid disorders was as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Unipolar depression, 73 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Any anxiety disorder, 64 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Obsessive-compulsive disorder, 21 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Avoidant personality disorder, 23 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Borderline personality disorder, 21 percent</p><p></p><p class="headingAnchor" id="H10289535"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Although the pathogenesis of depersonalization/derealization disorder (DDD) has not been established, it is generally assumed that the syndrome becomes manifest in individuals who have an inherent dissociative diathesis combined with psychological and/or chemical stressors.</p><p class="headingAnchor" id="H820260"><span class="h2">Role of trauma</span><span class="headingEndMark"> — </span>Acute depersonalization and derealization are quintessential responses to acute trauma (such as a motor vehicle accident) or other life-threatening experiences [<a href="#rid12">12,13</a>], speculated to be hardwired into the brain so that a sense of distance and detachment from the traumatic event can facilitate surviving and negotiating the event without experiencing overwhelming, disorganizing emotion (ie, “going through the motions”) [<a href="#rid12">12,13</a>]. However, acute depersonalization and derealization symptoms occurring in the above circumstances typically clear within minutes, hours, or days, and do not become chronic. Chronic depersonalization and derealization symptoms qualifying for the disorder are more common among persons experiencing chronic traumatic or highly stressful situations such as verbal or emotional abuse or neglect during childhood [<a href="#rid10">10,14</a>].</p><p>Other traumatic antecedents include growing up with a parent or caregiver who had severe mental illness, traumatically struggling with sexual orientation or identity, and experiencing the unexpected death or suicide of a family member or close friend. Sexual abuse and physical abuse are less common antecedents of DDD than emotional maltreatment but clearly occur (see above). Numerous other chronic life stressors (interpersonal, financial, or occupational) have been associated with onset or exacerbation of DDD. Examples include loss of a relationship or divorce, or job loss, or social ostracization. It should be noted, however, that acute, short-lived traumas or stressors can trigger the onset of the disorder as well. (See <a class="local">'Risk factors'</a> above.)</p><p>The traumas reported by DDD patients are generally of a different nature than those typically reported by patients with other dissociative disorders such as dissociative identity disorder [<a href="#rid10">10,14</a>], centering on emotional maltreatment rather than sexual abuse. (See  <a class="medical medical_review" href="/z/d/html/14700.html" rel="external">"Dissociative identity disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis"</a>.)</p><p>In a cumulative sample of 93 adults with DDD compiled across several research studies, application of established clinically significant childhood maltreatment cutoff scores for the Childhood Trauma Questionnaire revealed that 63 percent of participants had experienced at least one form of maltreatment, predominantly emotional abuse and/or neglect (55 percent). Additionally, physical neglect was endorsed by 40 percent, physical abuse by 27 percent, and sexual abuse 20 percent [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H253900"><span class="h2">Organic precursors</span><span class="headingEndMark"> — </span>Common organic risk factors for depersonalization and derealization include seizures, mild to moderate head injury, brain tumors, and sleep apnea [<a href="#rid16">16</a>]. In such cases the diagnosis of the disorder is not made, as it requires the exclusion of such “organic” underpinnings.</p><p>Substance use is known to precipitate chronic depersonalization in some people [<a href="#rid17">17</a>]. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>These individuals can thus be conceptualized as having a neurobiological or genetic vulnerability to the onset of chronic depersonalization and derealization (ie, DDD), after drug use. A large survey study has shown that the characteristics and course of the condition do not differ between drug-induced and non-drug-induced cases [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H409471"><span class="h2">Neurobiology</span><span class="headingEndMark"> — </span>Several neurotransmitter systems, brain regions, and functional circuits have been associated with depersonalization and derealization symptoms with some consistency and are summarized below [<a href="#rid18">18</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>NMDA (N-methyl-D-aspartate) system</strong> – NMDA receptors are widely distributed in the cortex, hippocampus, and amygdala, and mediate associative processes. The NMDA antagonist <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a> induces a profound dissociative state in healthy subjects that is distinct, both phenomenologically and in the implicated brain pathways, from the psychotomimetic effects of ketamine [<a href="#rid19">19,20</a>]. Ketamine has complex pharmacodynamics and effects on other neurotransmitter systems, including Kappa opioid receptors that could relate to the acute induction of depersonalization and derealization [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endogenous cannabinoid system</strong> – Cannabis has been experimentally shown to induce depersonalization in healthy volunteers, with a pronounced component of temporal disintegration, and particular brain regions have been implicated [<a href="#rid22">22</a>]. Cannabinoids block NMDA receptors at sites distinct from other noncompetitive NMDA antagonists [<a href="#rid23">23</a>] and therefore their dissociative effect may be partly mediated via NMDA antagonism, as well as by the endogenous cannabinoid system. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kappa opioid agonists</strong> – The illicit drug salvia, which acts as a selective kappa opioid agonist, has been found to precipitate chronic depersonalization [<a href="#rid17">17,24</a>]. Nonselective antagonists such as <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">naloxone</a>, <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a>, and <a class="drug drug_general" data-topicid="135038" href="/z/d/drug information/135038.html" rel="external">nalmefene</a>, which have varying affinity for the kappa receptor, have been reported to diminish dissociative symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Serotonin agonists</strong> – Hallucinogens act as agonists at serotonin 5HT2A and especially 5HT2C receptors. Experimental challenge studies with the partial 5HT2A and C agonist m-CPP have demonstrated the induction of depersonalization in a mixed group of social phobia, borderline personality disorder, and obsessive-compulsive disorder participants [<a href="#rid25">25</a>], the induction of flashbacks and dissociative symptoms in a subgroup of posttraumatic stress disorder patients [<a href="#rid26">26</a>], and the induction of dissociation in healthy volunteers [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autonomic hypo-reactivity</strong> – There is some evidence for autonomic hypo-reactivity in DDD [<a href="#rid28">28,29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypothalamic-pituitary-adrenal (HPA) axis</strong> – The HPA axis has been investigated in DDD with conflicting findings. While one study reported nonsignificantly lower basal salivary cortisol in DDD subjects compared to healthy ones [<a href="#rid30">30,31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuroimaging</strong> – Neuroimaging studies show evidence for the following in DDD:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sensory integration occurring in the temporoparietal junction, in particular in the right hemisphere, has been implicated in out-of-body experiences [<a href="#rid32">32</a>]. Altered activity in this area has been shown by positron emission tomography scans [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Functional magnetic resonance imaging studies have implicated hypoactivation of the limbic system, in particular the insula, driven by heightened prefrontal inhibition, in the hypoemotionality and overthinking of DDD [<a href="#rid34">34-36</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Specific brain regions are involved in the experience of dissociation, such as the retrosplenial cortex [<a href="#rid37">37</a>]. Additionally, evidence suggests that the sense of self and one’s physical location within a spatial environment is processed in the posteromedial cortex [<a href="#rid38">38</a>]. Trauma-related derealization has been identified as involving increased ventromedial prefrontal cortex activation and its decreased resting-state connectivity with the cerebellum and orbitofrontal cortex [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Deficient representation of visceral-afferent neural signals at the brainstem level [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Evidence of less effective arousal suppression under cognitive stress [<a href="#rid41">41</a>] and a higher sympathetic tone [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Distinct brain correlates for anxiety, depression, somatization, and dissociation symptoms [<a href="#rid43">43</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Grey matter alterations [<a href="#rid44">44,45</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Heightened activation in several brain areas associated with self-processing [<a href="#rid46">46</a>].</p><p></p><p>The relationship between genes and DDD is not known. An analysis of proband-based family history data in 117 subjects with DDD found a heritability rate of only 5 percent [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H10289542"><span class="h2">Psychotherapeutic models</span><span class="headingEndMark"> — </span>Conceptual models for DDD have been developed from cognitive-behavioral and psychodynamic perspectives; these are described separately. (See  <a class="medical medical_review" href="/z/d/html/14695.html" rel="external">"Depersonalization/derealization disorder: Psychotherapy", section on 'Psychodynamic therapy'</a> and  <a class="medical medical_review" href="/z/d/html/14695.html" rel="external">"Depersonalization/derealization disorder: Psychotherapy"</a>.)</p><p class="headingAnchor" id="H10289563"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Patients experiencing depersonalization and derealization often have great difficulty putting their impalpable experiences into words. Unfamiliarity with these symptoms may lead individuals to fear that they may be taken for “crazy” or will become crazy. This is especially common in those raised in homes with mental illness, those prone to hypochondriasis and ruminations, and those who fear that a drug ingestion has caused irreversible brain damage. Clinicians’ typical focus on comorbid symptoms such as mood and anxiety often contributes to underdiagnosis or misdiagnosis of depersonalization/derealization disorder (DDD).</p><p>Symptoms, although quite specific, may sound vague or metaphorical rather than clear subjective experiences, such as “feeling dead,” “everything is unreal,” “I don’t feel I’m the one doing anything,” “it’s like I’m watching a movie,” etc. The symptoms are typically extremely distressing, at times crippling, and are associated with major morbidity and some mortality. The affectively flattened and robotic demeanor that these patients often demonstrate can also fool the clinician into not recognizing the extreme emotional pain of the condition. It is not uncommon, for example, for patients to wonder whether it would really matter if they died as they already feel dead. Suicide attempts are associated with DDD; however, given the high rates of comorbid depression and other psychiatric disorders in DDD, the relationship between suicidality and DDD remains unclear [<a href="#rid8">8,17</a>]. (See <a class="local">'Comorbid conditions'</a> above.)</p><p>Two factor analytic studies of the core symptomatology have reported five discrete symptom clusters common in patients with DDD [<a href="#rid47">47,48</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Unreality of self, defined as feeling detached from one’s physical body, mind and thoughts</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Perceptual alterations, which encompasses visual, tactile, and somatosensory distortions</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Emotional numbing, characterized by blunted affect, pain and volition</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anomalous subjective recall, which consists of disrupted experiences of time and related imagery</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alienation from surroundings, which comprises symptoms of derealization</p><p></p><p class="headingAnchor" id="H1109790121"><span class="h1">COURSE</span><span class="headingEndMark"> — </span>Depersonalization/derealization disorder (DDD) can have an episodic, relapsing/remitting, or chronic course. In a series of 117 cases of patients with DDD, approximately one-third of individuals had an episodic course; one-third had a continuous course from time of onset; and one-third initially had an episodic course that over time became continuous [<a href="#rid8">8</a>].</p><p>Many patients with chronic depersonalization and derealization experience marked impairment in occupational, social, and personal functioning. In a study comparing 223 patients with DDD with a sample of patients with depressive disorders without comorbid depersonalization/derealization, the two groups differed markedly in clinical presentation and course. DDD patients were younger, significantly more male, had a longer illness duration, earlier age of onset, and tended to show greater functional impairment [<a href="#rid49">49</a>].</p><p>Available research suggests that onset is most commonly in late adolescence or early adulthood, with onset of the disorder rarely occurring as late as the fourth or fifth decade of life [<a href="#rid8">8</a>]. Onset may be very sudden or insidious. Most patients with DDD are initially treated for secondary anxiety and mood disorder symptoms; the primary nature of the DDD may not be recognized until later. Once chronic depersonalization has set in, new traumatic or stressful events or episodes of other illness may lead to exacerbations of the symptoms.</p><p>Depersonalization or derealization that follows acute traumatic or stressful experiences or intoxication is often transient and remits spontaneously [<a href="#rid3">3</a>]. In our clinical experience, depersonalization accompanying mood or anxiety disorder episodes commonly remits with timely treatment of these conditions, but runs the risk of becoming more chronic and difficult to treat over time. In some cases, dissociation persists long after the initial precipitants and can become more refractory to treatment.</p><p class="headingAnchor" id="H10289577"><span class="h1">ASSESSMENT AND DIAGNOSIS</span></p><p class="headingAnchor" id="H604154889"><span class="h2">Assessment</span><span class="headingEndMark"> — </span>We undertake a diagnostic assessment including detailed psychiatric history, medical history, and mental status examination and cursory physical examination in all individuals with suspected depersonalization/derealization disorder (DDD). A thorough medical and neurologic evaluation is not routinely necessary; however, we conduct these evaluations in all patients presenting with atypical symptoms or illness course, of older age, or a general medical status or history that raises concerns about the differential diagnosis. (See <a class="local">'Differential diagnosis'</a> below.)</p><p>We obtain brain imaging (eg, computed tomography or magnetic resonance imaging) and ambulatory electroencephalogram (EEG) in cases of diagnostic ambiguity or in the presence of atypical symptoms (eg, blackouts, unexplained subtle motor or sensory symptoms, intermittent episodes that are difficult to correlate with any precipitants), seizures, or a family history of epilepsy. For example, we obtain brain imaging, EEG, and basic metabolic panel in individuals.</p><p class="bulletIndent1"><span class="glyph">●</span>Age of 40 or greater; onset is unusual at this age (see <a class="local">'Risk factors'</a> above)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Focal findings on neurologic examination</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of head injury, seizure disorder, or any brain lesions</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of any medical illness that could be associated with altered brain structure and function (eg, autoimmune disease)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suspicion of sleep apnea</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suspicion of Lyme disease or other infectious processes</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Family history of neurologic or related diseases</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Any atypical symptoms such as numbness, tingling, or head pressure sensations</p><p></p><p>We obtain urine toxicology screening if history or examination suggests the possibility of a substance use disorder, although patients with DDD will typically refrain from any further substance use once the disorder sets in and even become phobic of such drug use [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H200208756"><span class="h3">Rating scales</span><span class="headingEndMark"> — </span>We typically use the Dissociative Experiences Scale (<a class="graphic graphic_table graphicRef57128" href="/z/d/graphic/57128.html" rel="external">table 1</a>). The scale has several items pertaining to depersonalization/derealization experiences whereas the endorsement of other items pertaining to amnesia and identity alteration should be essentially very low or absent [<a href="#rid50">50-52</a>]. More specific to the disorder, the Cambridge Depersonalization Scale is a self-report questionnaire comprised of 29 items which rate both frequency and duration of depersonalization/derealization experiences (<a class="graphic graphic_table graphicRef80001" href="/z/d/graphic/80001.html" rel="external">table 2</a>). A total score of 70 has been shown to reliably differentiate DDD patients from those with various mood, anxiety, or neurologic disorders [<a href="#rid53">53</a>].</p><p>We find self-report questionnaires to be helpful in affirming the diagnosis of DDD. This may be especially useful for clinicians who are not as extensively familiar with dissociative symptoms. </p><p class="headingAnchor" id="H93996434"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>DDD is diagnosed using the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) diagnostic criteria [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A. The presence of persistent or recurrent experiences of depersonalization, derealization, or both:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>1. <strong>Depersonalization</strong> – Experiences of unreality, detachment, or being an outside observer with respect to one's thoughts, feelings, sensations, body, or actions (eg, perceptual alterations, distorted sense of time, unreal or absent self, emotional and/or physical numbing).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>2. <strong>Derealization</strong> – Experiences of unreality or detachment with respect to surroundings (eg, individuals or objects are experienced as unreal, dreamlike, foggy, lifeless, or visually distorted).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>B. During the depersonalization or derealization experiences, reality testing remains intact.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>C. The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>D. The disturbance is not attributable to the physiological effects of an illicit substance, medication, or another medical condition (eg, seizures).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>E. The disturbance is not better explained by another mental disorder such as schizophrenia, panic disorder, major depressive disorder, acute stress disorder, posttraumatic stress disorder (PTSD), or another dissociative disorder. (See <a class="local">'Differential diagnosis'</a> below.)</p><p></p><p>Depersonalization and derealization that follow traumatic or stressful experiences or intoxication commonly remit spontaneously. Our clinical experience suggests that it may not be useful or effective to diagnose and treat DDD unless the symptoms continue for a month or possibly longer. The DSM-5-TR diagnostic criteria for DDD do not specify a minimal duration of symptoms [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H2022362"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>A detailed psychiatric history and mental status examination can distinguish DDD from other mental disorders and medical conditions. Depersonalization or derealization can present as a symptom of other mental disorders. We differentiate these by the following symptoms or symptom patterns:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Schizophrenia or other psychotic spectrum disorder</strong> – Individuals with DDD have intact reality testing whereas in individuals with schizophrenia or other psychotic spectrum disorder reality testing is typically not intact. Additionally in prodromal psychotic syndromes, perceptual alterations are often accompanied by magical ideation-type interpretations of the symptoms whereas this is not seen in DDD. For example, a person with DDD may feel like they are a zombie, but knows they are not a zombie. A study comparing perceptual alterations and magical ideation in patients with DDD and healthy volunteers found that people with the disorder only had elevated perceptual, but not cognitive, distortions [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/z/d/html/6962.html" rel="external">"Schizophrenia in adults: Clinical features, assessment, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Panic disorder</strong> – While both panic disorder and DDD may present with symptoms of derealization or depersonalization, individuals with panic disorder have recurrent unexpected surges of intense fear or discomfort that reaches a peak within minutes and are associated with symptoms such as palpitations, sweating, trembling, chest pain or dizziness. These are not typically seen in DDD. (See  <a class="medical medical_review" href="/z/d/html/14628.html" rel="external">"Panic disorder in adults: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Major depressive disorder</strong> – We differentiate DDD from depressive disorder by the presence of depressed mood, diminished interest or pleasure in most or all activities, changes in sleep pattern (insomnia, hypersomnia), fatigue, feelings of worthlessness or guilt, and psychomotor changes that are typically seen in major depressive disorder. These symptoms are not typically seen in DDD.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute stress disorder </strong>– While both DDD and acute stress disorder may have dissociative symptoms, in acute stress disorder the symptoms last for three days to one month and are associated with symptoms such as intrusions, avoidance of distressing memories or external reminders of the traumatic event, and symptoms of altered arousal (eg, sleep disturbance, hypervigilance, exaggerated startle reflex.) These are not commonly seen in DDD. (See  <a class="medical medical_review" href="/z/d/html/14616.html" rel="external">"Acute stress disorder in adults: Epidemiology, clinical features, assessment, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Posttraumatic stress disorder</strong> – We distinguish PTSD from DDD by the presence of intrusion symptoms (ie, flashbacks, persistent avoidance of stimuli associated with the traumatic event), and symptoms of altered arousal that are commonly seen in PTSD. (See  <a class="medical medical_review" href="/z/d/html/14699.html" rel="external">"Dissociative aspects of posttraumatic stress disorder: Epidemiology, clinical manifestations, assessment, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other dissociative disorders</strong> – Individuals with DDD do not have distinct personality states as in dissociative identity disorder. Individuals with DDD do not have an inability to recall important autobiographical information as in dissociative amnesia. (See  <a class="medical medical_review" href="/z/d/html/14700.html" rel="external">"Dissociative identity disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Personality disorders </strong>– Individuals with personality disorders or DDD may manifest symptoms such as depersonalization or derealization. However, in personality disorders, the enduring pattern of inner experience or behavior is manifested by changes in cognition, affect, interpersonal functioning, or impulse control. The behaviors are inflexible and pervasive across a broad range of personal and social situations, stable and of long duration, and lead to significant distress or impairment in psychosocial functioning. (See  <a class="medical medical_review" href="/z/d/html/6619.html" rel="external">"Borderline personality disorder: Epidemiology, pathogenesis, clinical features, course, assessment, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other medical or neurologic conditions </strong>–<strong> </strong>Chronic depersonalization and derealization may less commonly result from a medical or neurologic condition (eg, temporal lobe epilepsy, mild to moderate brain trauma) [<a href="#rid55">55,56</a>], or be secondary to a substance use disorder (most commonly marijuana, hallucinogens, <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a>, and salvia) [<a href="#rid17">17,57</a>]. Rare cases have been seen with vestibular pathology or sleep apnea as the underlying cause. (See <a class="local">'Assessment'</a> above and  <a class="medical medical_review" href="/z/d/html/2231.html" rel="external">"Focal epilepsy: Causes and clinical features", section on 'Seizure semiology'</a> and  <a class="medical medical_review" href="/z/d/html/7796.html" rel="external">"Cannabis use disorder: Clinical features, screening, diagnosis, and treatment"</a> and  <a class="medical medical_review" href="/z/d/html/5102.html" rel="external">"Vestibular neuritis and labyrinthitis"</a>.)</p><p></p><p class="headingAnchor" id="H67851341"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/120256.html" rel="external">"Society guideline links: Dissociative disorders"</a>.)</p><p class="headingAnchor" id="H819630"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction and definitions</strong> – Depersonalization/derealization disorder (DDD) is characterized by the persistence or recurrence of depersonalization and/or derealization that cause clinically significant distress or impairment in the presence of intact reality testing (see <a class="local">'Assessment and diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Depersonalization is a persistent or recurrent feeling of detachment or estrangement from one’s self</p><p class="bulletIndent2"><span class="glyph">•</span>Derealization is a subjective sense of detachment or unreality regarding the world around them</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Transient experiences of depersonalization and/or derealization are very common, while DDD has a prevalence of approximately two percent. DDD has high rates of comorbidity with depression and anxiety disorders as well as avoidant and borderline personality disorders. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of trauma </strong>– While the pathogenesis of DDD has not been established, chronic depersonalization and derealization symptoms qualifying for the disorder are more common among persons experiencing chronic traumatic or highly stressful situations such as verbal or emotional abuse or neglect during childhood.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Organic precursors</strong> – Common organic risk factors for depersonalization include seizures, mild to moderate head injury, and substance use disorder. Several neurotransmitter systems, brain areas, and functional circuits have been associated with depersonalization with some consistency in research studies. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – Studies of patients with DDD suggest that five discrete symptoms clusters commonly appear in the disorder (see <a class="local">'Clinical manifestations'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unreality of self</p><p class="bulletIndent2"><span class="glyph">•</span>Perceptual alterations</p><p class="bulletIndent2"><span class="glyph">•</span>Emotional numbing</p><p class="bulletIndent2"><span class="glyph">•</span>Anomalous subjective recall</p><p class="bulletIndent2"><span class="glyph">•</span>Alienation from surroundings</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment</strong> – We undertake a diagnostic assessment including detailed psychiatric history, medical history and mental status examination and cursory physical examination in all individuals with suspected DDD. A thorough medical and neurologic evaluation is not routinely necessary; however, we conduct these evaluations in all patients presenting with atypical symptoms or illness course, of older age, or a general medical status or history that raises concerns about the differential diagnosis. (See <a class="local">'Assessment and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – We differentiate DDD from other disorders that may present with symptoms of depersonalization/derealization. These include (see <a class="local">'Differential diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Schizophrenia or other psychotic spectrum disorders</p><p class="bulletIndent2"><span class="glyph">•</span>Panic disorder</p><p class="bulletIndent2"><span class="glyph">•</span>Major depression</p><p class="bulletIndent2"><span class="glyph">•</span>Acute stress disorder</p><p class="bulletIndent2"><span class="glyph">•</span>Posttraumatic stress disorder</p><p class="bulletIndent2"><span class="glyph">•</span>Other dissociative disorders</p><p class="bulletIndent2"><span class="glyph">•</span>Personality disorders</p><p class="bulletIndent2"><span class="glyph">•</span>General medical conditions such as temporal lobe epilepsy, mild to moderate brain trauma, brain tumors</p><p class="bulletIndent2"><span class="glyph">•</span>Substance use disorder: marijuana, hallucinogens, <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">ketamine</a>, and salvia</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), Washington, DC 2022.</li><li class="breakAll">Cattell JP, Cattell JS. Depersonalization: Psychological and social perspectives. In: American Handbook of Psychiatry, Arieti S (Ed), Basic Books, New York 1974.</li><li><a class="nounderline abstract_t">Aderibigbe YA, Bloch RM, Walker WR. Prevalence of depersonalization and derealization experiences in a rural population. Soc Psychiatry Psychiatr Epidemiol 2001; 36:63.</a></li><li><a class="nounderline abstract_t">Michal M, Duven E, Giralt S, et al. Prevalence and correlates of depersonalization in students aged 12-18 years in Germany. Soc Psychiatry Psychiatr Epidemiol 2015; 50:995.</a></li><li><a class="nounderline abstract_t">Ross CA, Joshi S, Currie R. Dissociative experiences in the general population: a factor analysis. Hosp Community Psychiatry 1991; 42:297.</a></li><li><a class="nounderline abstract_t">Hunter EC, Sierra M, David AS. The epidemiology of depersonalisation and derealisation. A systematic review. Soc Psychiatry Psychiatr Epidemiol 2004; 39:9.</a></li><li><a class="nounderline abstract_t">Johnson JG, Cohen P, Kasen S, Brook JS. Dissociative disorders among adults in the community, impaired functioning, and axis I and II comorbidity. J Psychiatr Res 2006; 40:131.</a></li><li><a class="nounderline abstract_t">Simeon D, Knutelska M, Nelson D, Guralnik O. Feeling unreal: a depersonalization disorder update of 117 cases. J Clin Psychiatry 2003; 64:990.</a></li><li><a class="nounderline abstract_t">Baker D, Hunter E, Lawrence E, et al. Depersonalisation disorder: clinical features of 204 cases. Br J Psychiatry 2003; 182:428.</a></li><li><a class="nounderline abstract_t">Simeon D, Giesbrecht T, Knutelska M, et al. Alexithymia, absorption, and cognitive failures in depersonalization disorder: a comparison to posttraumatic stress disorder and healthy volunteers. J Nerv Ment Dis 2009; 197:492.</a></li><li><a class="nounderline abstract_t">Simeon D, Knutelska M. The role of fearful attachment in depersonalization disorder. European Journal of Trauma &amp; Dissociation 2022; 6.</a></li><li><a class="nounderline abstract_t">Noyes R Jr, Hoenk PR, Kuperman S, Slymen DJ. Depersonalization in accident victims and psychiatric patients. J Nerv Ment Dis 1977; 164:401.</a></li><li><a class="nounderline abstract_t">Noyes R Jr, Kletti R. Depersonilization in response to life-threatening danger. Compr Psychiatry 1977; 18:375.</a></li><li><a class="nounderline abstract_t">Simeon D, Guralnik O, Schmeidler J, et al. The role of childhood interpersonal trauma in depersonalization disorder. Am J Psychiatry 2001; 158:1027.</a></li><li class="breakAll">Simeon D, Abugel J. Feeling Unreal: Depersonalization Disorder and the Loss of the Self, 2nd ed, Oxford University Press.</li><li><a class="nounderline abstract_t">Grigsby J, Kaye K. Incidence and correlates of depersonalization following head trauma. Brain Inj 1993; 7:507.</a></li><li><a class="nounderline abstract_t">Simeon D, Kozin DS, Segal K, Lerch B. Is depersonalization disorder initiated by illicit drug use any different? A survey of 394 adults. J Clin Psychiatry 2009; 70:1358.</a></li><li><a class="nounderline abstract_t">Simeon D. Depersonalisation disorder: a contemporary overview. CNS Drugs 2004; 18:343.</a></li><li><a class="nounderline abstract_t">Anand A, Charney DS, Oren DA, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 2000; 57:270.</a></li><li><a class="nounderline abstract_t">Deakin JF, Lees J, McKie S, et al. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry 2008; 65:154.</a></li><li><a class="nounderline abstract_t">Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg 1998; 87:1186.</a></li><li><a class="nounderline abstract_t">Mathew RJ, Wilson WH, Chiu NY, et al. Regional cerebral blood flow and depersonalization after tetrahydrocannabinol administration. Acta Psychiatr Scand 1999; 100:67.</a></li><li><a class="nounderline abstract_t">Feigenbaum JJ, Bergmann F, Richmond SA, et al. Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker. Proc Natl Acad Sci U S A 1989; 86:9584.</a></li><li><a class="nounderline abstract_t">Walsh SL, Strain EC, Abreu ME, Bigelow GE. Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl) 2001; 157:151.</a></li><li><a class="nounderline abstract_t">Simeon D, Hollander E, Stein DJ, et al. Induction of depersonalization by the serotonin agonist meta-chlorophenylpiperazine. Psychiatry Res 1995; 58:161.</a></li><li><a class="nounderline abstract_t">Southwick SM, Krystal JH, Bremner JD, et al. Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch Gen Psychiatry 1997; 54:749.</a></li><li><a class="nounderline abstract_t">D'Souza DC, Gil RB, Zuzarte E, et al. gamma-Aminobutyric acid-serotonin interactions in healthy men: implications for network models of psychosis and dissociation. Biol Psychiatry 2006; 59:128.</a></li><li><a class="nounderline abstract_t">Sierra M, Senior C, Dalton J, et al. Autonomic response in depersonalization disorder. Arch Gen Psychiatry 2002; 59:833.</a></li><li><a class="nounderline abstract_t">Simeon D, Guralnik O, Knutelska M, et al. Basal norepinephrine in depersonalization disorder. Psychiatry Res 2003; 121:93.</a></li><li><a class="nounderline abstract_t">Stanton BR, David AS, Cleare AJ, et al. Basal activity of the hypothalamic-pituitary-adrenal axis in patients with depersonalization disorder. Psychiatry Res 2001; 104:85.</a></li><li><a class="nounderline abstract_t">Simeon D, Knutelska M, Yehuda R, et al. Hypothalamic-pituitary-adrenal axis function in dissociative disorders, post-traumatic stress disorder, and healthy volunteers. Biol Psychiatry 2007; 61:966.</a></li><li><a class="nounderline abstract_t">Blanke O, Ortigue S, Landis T, Seeck M. Stimulating illusory own-body perceptions. Nature 2002; 419:269.</a></li><li><a class="nounderline abstract_t">Simeon D, Guralnik O, Hazlett EA, et al. Feeling unreal: a PET study of depersonalization disorder. Am J Psychiatry 2000; 157:1782.</a></li><li><a class="nounderline abstract_t">Phillips ML, Medford N, Senior C, et al. Depersonalization disorder: thinking without feeling. Psychiatry Res 2001; 108:145.</a></li><li><a class="nounderline abstract_t">Lemche E, Surguladze SA, Giampietro VP, et al. Limbic and prefrontal responses to facial emotion expressions in depersonalization. Neuroreport 2007; 18:473.</a></li><li><a class="nounderline abstract_t">Lanius RA, Vermetten E, Loewenstein RJ, et al. Emotion modulation in PTSD: Clinical and neurobiological evidence for a dissociative subtype. Am J Psychiatry 2010; 167:640.</a></li><li><a class="nounderline abstract_t">Vesuna S, Kauvar IV, Richman E, et al. Deep posteromedial cortical rhythm in dissociation. Nature 2020; 586:87.</a></li><li><a class="nounderline abstract_t">Lyu D, Stieger JR, Xin C, et al. Causal evidence for the processing of bodily self in the anterior precuneus. Neuron 2023; 111:2502.</a></li><li><a class="nounderline abstract_t">Lebois LAM, Harnett NG, van Rooij SJH, et al. Persistent Dissociation and Its Neural Correlates in Predicting Outcomes After Trauma Exposure. Am J Psychiatry 2022; 179:661.</a></li><li><a class="nounderline abstract_t">Schulz A, Matthey JH, Vögele C, et al. Cardiac modulation of startle is altered in depersonalization-/derealization disorder: Evidence for impaired brainstem representation of baro-afferent neural traffic. Psychiatry Res 2016; 240:4.</a></li><li><a class="nounderline abstract_t">Lemche E, Sierra-Siegert M, David AS, et al. Cognitive load and autonomic response patterns under negative priming demand in depersonalization-derealization disorder. Eur J Neurosci 2016; 43:971.</a></li><li><a class="nounderline abstract_t">Schulz A, Köster S, Beutel ME, et al. Altered patterns of heartbeat-evoked potentials in depersonalization/derealization disorder: neurophysiological evidence for impaired cortical representation of bodily signals. Psychosom Med 2015; 77:506.</a></li><li><a class="nounderline abstract_t">Lemche E, Surguladze SA, Brammer MJ, et al. Dissociable brain correlates for depression, anxiety, dissociation, and somatization in depersonalization-derealization disorder. CNS Spectr 2016; 21:35.</a></li><li><a class="nounderline abstract_t">Sierra M, Nestler S, Jay EL, et al. A structural MRI study of cortical thickness in depersonalisation disorder. Psychiatry Res 2014; 224:1.</a></li><li><a class="nounderline abstract_t">Daniels JK, Gaebler M, Lamke JP, Walter H. Grey matter alterations in patients with depersonalization disorder: a voxel-based morphometry study. J Psychiatry Neurosci 2015; 40:19.</a></li><li><a class="nounderline abstract_t">Ketay S, Hamilton HK, Haas BW, Simeon D. Face processing in depersonalization: an fMRI study of the unfamiliar self. Psychiatry Res 2014; 222:107.</a></li><li><a class="nounderline abstract_t">Sierra M, Baker D, Medford N, David AS. Unpacking the depersonalization syndrome: an exploratory factor analysis on the Cambridge Depersonalization Scale. Psychol Med 2005; 35:1523.</a></li><li><a class="nounderline abstract_t">Simeon D, Kozin DS, Segal K, et al. De-constructing depersonalization: further evidence for symptom clusters. Psychiatry Res 2008; 157:303.</a></li><li><a class="nounderline abstract_t">Michal M, Adler J, Wiltink J, et al. A case series of 223 patients with depersonalization-derealization syndrome. BMC Psychiatry 2016; 16:203.</a></li><li><a class="nounderline abstract_t">Bernstein EM, Putnam FW. Development, reliability, and validity of a dissociation scale. J Nerv Ment Dis 1986; 174:727.</a></li><li><a class="nounderline abstract_t">Bernstein-Carlson E, Putnam FW. An update on the Disssociative Experiences Scale. Dissociation 1993; 6:16.</a></li><li><a class="nounderline abstract_t">van Ijzendoorn MH, Schuengel C. The measurement of dissociation in normal and clinical populations: meta-analytic validation of the dissociative experiences scale (DES). Clin Psychol Rev 1996; 16:365.</a></li><li><a class="nounderline abstract_t">Sierra M, Berrios GE. The Cambridge Depersonalization Scale: a new instrument for the measurement of depersonalization. Psychiatry Res 2000; 93:153.</a></li><li><a class="nounderline abstract_t">Simeon D, Guralnik O. Dissection of schizotypy and dissociation in depersonalization disorder. J Trauma and Dissociation 2004; 5:111.</a></li><li><a class="nounderline abstract_t">Lambert MV, Senior C, Fewtrell WD, et al. Primary and secondary depersonalisation disorder: a psychometric study. J Affect Disord 2001; 63:249.</a></li><li><a class="nounderline abstract_t">Sierra M, Lopera F, Lambert MV, et al. Separating depersonalisation and derealisation: the relevance of the "lesion method". J Neurol Neurosurg Psychiatry 2002; 72:530.</a></li><li><a class="nounderline abstract_t">Medford N, Baker D, Hunter E, et al. Chronic depersonalization following illicit drug use: a controlled analysis of 40 cases. Addiction 2003; 98:1731.</a></li></ol></div><div id="topicVersionRevision">Topic 16700 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), Washington, DC 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Cattell JP, Cattell JS. Depersonalization: Psychological and social perspectives. In: American Handbook of Psychiatry, Arieti S (Ed), Basic Books, New York 1974.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11355447" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prevalence of depersonalization and derealization experiences in a rural population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25201182" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence and correlates of depersonalization in students aged 12-18 years in Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2030014" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Dissociative experiences in the general population: a factor analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15022041" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The epidemiology of depersonalisation and derealisation. A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16337235" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Dissociative disorders among adults in the community, impaired functioning, and axis I and II comorbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14628973" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Feeling unreal: a depersonalization disorder update of 117 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12724246" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Depersonalisation disorder: clinical features of 204 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19597356" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Alexithymia, absorption, and cognitive failures in depersonalization disorder: a comparison to posttraumatic stress disorder and healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The role of fearful attachment in depersonalization disorder</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/864453" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Depersonalization in accident victims and psychiatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/872561" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Depersonilization in response to life-threatening danger.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11431223" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The role of childhood interpersonal trauma in depersonalization disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11431223" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The role of childhood interpersonal trauma in depersonalization disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8260954" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Incidence and correlates of depersonalization following head trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19538903" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Is depersonalization disorder initiated by illicit drug use any different? A survey of 394 adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15089102" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Depersonalisation disorder: a contemporary overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10711913" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18250253" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9806706" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Ketamine: teaching an old drug new tricks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10442442" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Regional cerebral blood flow and depersonalization after tetrahydrocannabinol administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2556719" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11594439" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8570768" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Induction of depersonalization by the serotonin agonist meta-chlorophenylpiperazine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9283511" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Noradrenergic and serotonergic function in posttraumatic stress disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16140281" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : gamma-Aminobutyric acid-serotonin interactions in healthy men: implications for network models of psychosis and dissociation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12215083" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Autonomic response in depersonalization disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14572626" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Basal norepinephrine in depersonalization disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11600192" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Basal activity of the hypothalamic-pituitary-adrenal axis in patients with depersonalization disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17137559" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hypothalamic-pituitary-adrenal axis function in dissociative disorders, post-traumatic stress disorder, and healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12239558" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Stimulating illusory own-body perceptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11058475" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Feeling unreal: a PET study of depersonalization disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11756013" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Depersonalization disorder: thinking without feeling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17496806" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Limbic and prefrontal responses to facial emotion expressions in depersonalization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20360318" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Emotion modulation in PTSD: Clinical and neurobiological evidence for a dissociative subtype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32939091" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Deep posteromedial cortical rhythm in dissociation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37295420" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Causal evidence for the processing of bodily self in the anterior precuneus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35730162" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Persistent Dissociation and Its Neural Correlates in Predicting Outcomes After Trauma Exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27078753" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cardiac modulation of startle is altered in depersonalization-/derealization disorder: Evidence for impaired brainstem representation of baro-afferent neural traffic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26791018" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cognitive load and autonomic response patterns under negative priming demand in depersonalization-derealization disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25984819" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Altered patterns of heartbeat-evoked potentials in depersonalization/derealization disorder: neurophysiological evidence for impaired cortical representation of bodily signals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24059962" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Dissociable brain correlates for depression, anxiety, dissociation, and somatization in depersonalization-derealization disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25089021" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : A structural MRI study of cortical thickness in depersonalisation disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25285875" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Grey matter alterations in patients with depersonalization disorder: a voxel-based morphometry study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24582597" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Face processing in depersonalization: an fMRI study of the unfamiliar self.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16164776" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Unpacking the depersonalization syndrome: an exploratory factor analysis on the Cambridge Depersonalization Scale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17959254" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : De-constructing depersonalization: further evidence for symptom clusters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27349226" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A case series of 223 patients with depersonalization-derealization syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3783140" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Development, reliability, and validity of a dissociation scale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : An update on the Disssociative Experiences Scale</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The measurement of dissociation in normal and clinical populations: meta-analytic validation of the dissociative experiences scale (DES)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10725532" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The Cambridge Depersonalization Scale: a new instrument for the measurement of depersonalization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Dissection of schizotypy and dissociation in depersonalization disorder</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11246104" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Primary and secondary depersonalisation disorder: a psychometric study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11909918" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Separating depersonalisation and derealisation: the relevance of the "lesion method".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14651505" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Chronic depersonalization following illicit drug use: a controlled analysis of 40 cases.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
